This small-cap pharmaceutical is up by 13.85% in a volatile market!

The shares of the company rallied after it reported robust quarterly results.

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics, and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

Financial Results Highlights

Despite the supply chain and price surge caused by the geopolitical crisis, the company maintained its upward trajectory and reported robust financial results for the June quarter.

In Q1FY23, on a standalone basis, the company’s revenue grew by 19.24% YoY to Rs 128.93 crore from Rs 108.13 crore in Q1FY22. PBIDT (ex. OI) was reported at Rs 27.84 crore, registering a growth of 21.31% YoY as compared to the year-ago period, which was Rs 22.95 crore. PAT was reported at Rs 18.21 crore against Rs 13.58 crore in the same quarter of the previous fiscal year, showcasing a YoY jump of 34.09%.

On a valuation front, this Group B stock has a P/E of 19.70x times. The company reported an RoE of 21.6%, while its RoCE stood at 31.10% as per the last audited annual report.

According to the statement of Yugal Sikri, Managing Director of RPG Life Sciences Ltd, the domestic formulation business has recorded a robust growth both in value and volumes - significantly and consistently better than the market. The new product portfolio comprising newer and progressive segments is also witnessing an impressive uptake. The company has successfully forayed into a new therapy area - Rheumatology, this has strengthened its presence in the Specialty segment. The international formulation business has also shown a robust recovery while the API business is growing at a decent pace. Its unique digital initiative, RPGServ, is having remarkable traction in physician connection and engagement. In the future, the company plans to stay committed to implementing its Transformation Agenda to grow both top-line and bottom-line across segments.

At 12:03 pm, the shares of the company have jumped by 13.85% and the scrip is trading at Rs 698.